Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective
Niraj Shenoy, Lance C. Pagliaro
Annals of Oncology (2016) Vol. 27, Iss. 9, pp. 1685-1695
Open Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

Epigenetics in renal cell cancer: mechanisms and clinical applications
Sophie C. Joosten, Kim M. Smits, Maureen J.B. Aarts, et al.
Nature Reviews Urology (2018) Vol. 15, Iss. 7, pp. 430-451
Closed Access | Times Cited: 136
A novel LncRNA HITT forms a regulatory loop with HIF-1α to modulate angiogenesis and tumor growth
Xingwen Wang, Li Li, Kunming Zhao, et al.
Cell Death and Differentiation (2019) Vol. 27, Iss. 4, pp. 1431-1446
Open Access | Times Cited: 79
Ascorbic acid–induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma
Niraj Shenoy, Tushar D. Bhagat, John C. Cheville, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 4, pp. 1612-1625
Open Access | Times Cited: 77
Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation
Tiansheng Li, Chao Mao, Xiang Wang, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 72
The Multifaceted Roles of Mast Cells in Immune Homeostasis, Infections and Cancers
Anna Sobiepanek, Łukasz Kuryk, Mariangela Garofalo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 4, pp. 2249-2249
Open Access | Times Cited: 40
HIF: a master regulator of nutrient availability and metabolic cross‐talk in the tumor microenvironment
Rindert Missiaen, Nicholas P. Lesner, M. Celeste Simon
The EMBO Journal (2023) Vol. 42, Iss. 6
Open Access | Times Cited: 35
Single-cell RNA-seq integrated with multi-omics reveals SERPINE2 as a target for metastasis in advanced renal cell carcinoma
Wenjin Chen, Keqin Dong, Xiuwu Pan, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 27
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma
Martin H. Voss, Arif Hussain, Nicholas J. Vogelzang, et al.
Annals of Oncology (2017) Vol. 28, Iss. 11, pp. 2754-2760
Open Access | Times Cited: 64
Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer
Ritesh K. Aggarwal, Rebecca A. Luchtel, Venkata R. Machha, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 39
Open Access | Times Cited: 50
A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression
Wentao Liu, Dianyun Ren, Wei Xiong, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 31
Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma
Jihua Tian, Jing Luo, Xing Zeng, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 2, pp. e008226-e008226
Open Access | Times Cited: 8
Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma
Ali Mehdi, Yasser Riazalhosseini
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 8, pp. 1774-1774
Open Access | Times Cited: 55
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
Nizar M. Tannir, Gisela Schwab, Viktor Grünwald
Current Oncology Reports (2017) Vol. 19, Iss. 2
Open Access | Times Cited: 53
Association of leptin, visfatin, apelin, resistin and adiponectin with clear cell renal cell carcinoma
Haiping Zhang, Jian Zou, Zhuoqun Xu, et al.
Oncology Letters (2016) Vol. 13, Iss. 1, pp. 463-468
Open Access | Times Cited: 48
Sunitinib increases the cancer stem cells and vasculogenic mimicry formation via modulating the lncRNA-ECVSR/ERβ/Hif2-α signaling
Miao He, Huan Yang, Hangchuan Shi, et al.
Cancer Letters (2021) Vol. 524, pp. 15-28
Closed Access | Times Cited: 34
Targeting apoptosis in clear cell renal cell carcinoma
Adam Kowalewski, Jędrzej Borowczak, Mateusz Maniewski, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116805-116805
Open Access | Times Cited: 5
MicroRNAs Associated with Von Hippel–Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review
Lisa-Maria Schanza, Maximilian Seles, Michael Stotz, et al.
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 11, pp. 2495-2495
Open Access | Times Cited: 44
Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment
Piotr Wierzbicki, Jakub Kłącz, Anna Kotulak‐Chrząszcz, et al.
International Journal of Oncology (2019)
Open Access | Times Cited: 40
Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy
Yongchang Lai, Tao Zeng, Xiongfa Liang, et al.
Cancer Cell International (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 40
Transferrin receptor-involved HIF-1 signaling pathway in cervical cancer
Xiaofeng Xu, Tao Liu, Jun Wu, et al.
Cancer Gene Therapy (2019) Vol. 26, Iss. 11-12, pp. 356-365
Closed Access | Times Cited: 36
Von Hippel–Lindau (VHL) small-molecule inhibitor binding increases stability and intracellular levels of VHL protein
Julianty Frost, Sónia Rocha, Alessio Ciulli
Journal of Biological Chemistry (2021) Vol. 297, Iss. 2, pp. 100910-100910
Open Access | Times Cited: 28
The SWI/SNF chromatin remodeling factor DPF3 regulates metastasis of ccRCC by modulating TGF-β signaling
Huanhuan Cui, Hongyang Yi, Hongyu Bao, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 20
The Tumor Suppressor Roles of MYBBP1A, a Major Contributor to Metabolism Plasticity and Stemness
Blanca Felipe‐Abrio, Amancio Carnero
Cancers (2020) Vol. 12, Iss. 1, pp. 254-254
Open Access | Times Cited: 30
Immune evasion in renal cell carcinoma: biology, clinical translation, future directions
Xiaoyang Wang, Robert Lopez, Rebecca A. Luchtel, et al.
Kidney International (2020) Vol. 99, Iss. 1, pp. 75-85
Open Access | Times Cited: 29
Facts and Hopes for Immunotherapy in Renal Cell Carcinoma
Chen Yao, Tian Zhang, Tuoqi Wu, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 23, pp. 5013-5020
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top